Brief: Cingulate Announces Successful Transfer Of Ctx-1301 (Dexmethylphenidate) Proprietary Ptr™ Manufacturing Processes To Societal Cdmo
03/05/2023 12:24
Cingulate Inc CING.O :
* CINGULATE ANNOUNCES SUCCESSFUL TRANSFER OF CTX-1301
(DEXMETHYLPHENIDATE) PROPRIETARY PTR™ MANUFACTURING PROCESSES TO
SOCIETAL CDMO
* CINGULATE INC- ASSUMING POSITIVE CLINICAL RESULTS FROM
PHASE 3
TRIALS, PLANS TO SUBMIT NDA FOR CTX-1301 IN MID-2024 UNDER
SECTION 505(B)(2) PATHWAY
* CINGULATE INC- PLANS TO COMMENCE ITS PIVOTAL PHASE 3
FIXED-DOSE
PEDIATRIC AND ADOLESCENT STUDY FOR CTX-1301 IN MID-2023
Source text for Eikon: ID:nGNX1G1pkY
Further company coverage: CING.O
Recent news on Societal CDMO
See all newsBrief: Corerx Inc Completes Acquisition Of Societal CDMO Inc
Societal CDMO Inc reports results for the quarter ended in December - Earnings Summary
Brief: Societal CDMO Inc Received Notice From Nasdaq Stating Co Regained Compliance With Nasdaq Listing Rule 5550(A)(2) On March 14
Brief: Societal Cdmo Enters Into Definitive Agreement To Be Acquired By Corerx, Inc.
Societal CDMO Inc expected to post a loss of 1 cent a share - Earnings Preview